Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vancomycin-stressed <i>Staphylococcus aureus</i> extracellular vesicles hijack macrophage autophagy to enhance bacterial intracellular survival.

Autophagy·2026
Same author

Effectiveness and gender-tailoring of suicide prevention interventions for men: a systematic review.

BMC public health·2026
Same author

Characteristics of specific DNA junction motifs inspired by natural RNA motifs.

International journal of biological macromolecules·2026
Same author

Network-Reconfigured Thermoelectric Flexible Sensor for Ultrafast Steady-State Temperature Perception.

ACS nano·2026
Same author

An explainable machine learning model for early pediatric sepsis prediction using cytokine and routine laboratory data.

Pediatric research·2026
Same author

Transitions and determinants of ICU-acquired frailty after critical illness: A multicenter cohort study using a multistate Markov model.

Annals of intensive care·2026

Related Experiment Video

Updated: May 10, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Treatment for papillary thyroid microcarcinoma.

Lan Shi1, Jun-Hua Chen, Shun-Tao Wang

  • 1Breast & Thyroid Surgery Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Contemporary Oncology (Poznan, Poland)
|June 22, 2013
PubMed
Summary

Papillary thyroid microcarcinoma (PTMC) often presents with multifocality and lymph node metastasis. Total thyroidectomy with central compartment node dissection is recommended for optimal surgical management of PTMC.

Keywords:
frozen section (FS)papillary thyroid microcarcinoma (PTMC)treatment

More Related Videos

Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma
04:01

Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma

Published on: September 15, 2023

Related Experiment Videos

Last Updated: May 10, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma
04:01

Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma

Published on: September 15, 2023

Area of Science:

  • Endocrinology
  • Oncology
  • Surgical Pathology

Background:

  • Papillary thyroid microcarcinoma (PTMC), defined as tumors less than 1 cm, presents a treatment controversy.
  • Retrospective evaluation of clinical and histopathological features is crucial for understanding PTMC behavior.

Purpose of the Study:

  • To retrospectively analyze clinical and histopathological features of 153 patients diagnosed with PTMC.
  • To determine the optimal surgical strategy for PTMC based on observed characteristics.

Main Methods:

  • Review of clinical and histopathological data from 153 consecutive PTMC patients.
  • Analysis of tumor diameter, histological variants, multifocality, capsular invasion, and lymph node metastasis.

Main Results:

  • PTMC exhibited a mean diameter of 5.8 mm, with 90.2% being classical type and 9.8% follicular variant.
  • Multifocality occurred in 24.2% of patients, and lymph node metastasis was observed in 48.1%.
  • High incidence of multifocality and lymph node metastasis in the level VI central compartment was noted.

Conclusions:

  • Total thyroidectomy and central compartment node dissection are suggested as the optimal surgical approach for PTMC.
  • Prompt diagnosis of PTMC via frozen tissue sections is recommended for all thyroid nodules, unless malignancy is already confirmed by cytology.